BeiGene's Q1 2025 Financial reportMarket TrendBeiGene's Q1 2025 report highlights a 50.2% revenue growth, with zanubrutinib sales exceeding 5 billion RMB and achieving its first quarterly profit under US GAAP. The company also advances its oncology pipeline globally.
Novo Nordisk's Q1 2025 Financial reportMarket TrendNovo Nordisk's Q1 2025 revenue surged 18% to $11.9B, driven by diabetes and obesity treatments. Wegovy sales soared 83%, while semaglutide products contributed 71% of total revenue.
Global Chemical Companies 2024 Financial reportMarket TrendQuarterly and annual 2024 financial highlights from major U.S. chemical and materials companies including Dow, DuPont, Ecolab, Celanese, Linde, Air Products, and more, with detailed revenue and profit comparisons.
Pfizer's Q1 2025 Financial reportMarket TrendPfizer's Q1 2025 earnings report highlights strong adjusted EPS growth despite revenue decline. Key drivers include Comirnaty and Vyndaqel, with cost savings and R&D efficiency boosting performance.
Eli Lilly's Q1 2025 Financial reportMarket TrendEli Lilly's Q1 2025 revenue surged 45% to $12.73B, driven by Mounjaro and Zepbound. U.S. GLP-1 prescription share hit 53.3%, surpassing Novo Nordisk. Key R&D and regulatory milestones achieved.
AstraZeneca's Q1 2025 Financial reportMarket TrendAstraZeneca's Q1 2025 revenue rose 10% to $13.59B, with strong growth in oncology and China contributing $1.8B. CEO highlights rich pipeline, U.S. expansion, and 2030 $80B revenue goal.
Novartis's Q1 2025 Financial report Market TrendNovartis reports strong Q1 2025 results with 12% sales growth, 27% core operating income increase, major FDA approvals, and raised full-year guidance amid robust innovation and strategic execution.
Sherwin-Williams's Q1 2025 Financial reportMarket TrendSherwin-Williams reported Q1 2025 revenue of $5.31B, driven by strong growth in protective and marine coatings. Despite global headwinds, the company maintained stable profits and reaffirmed full-year guidance.
WuXi AppTec's Q1 2025 Financial reportMarket TrendWuXi AppTec reports strong Q1 2025 results with net profit up 89% YoY and orders reaching RMB 52.33 billion. Its CRDMO model drives growth across chemistry, testing, and biology services, showing resilience amid global challenges.
Gilead's Q1 2025 Financial report Financial statementsGilead's Q1 2025 report shows stable revenue, strong HIV and hepatitis sales growth, major R&D progress, and reaffirmed full-year guidance, driven by products like Biktarvy, Trodelvy, and lenacapavir.
